4 January 2021
At 7.30 am today, dialysis patient Brian Pinker became the very first person to be vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, with patients at the Oxford University NHS Hospitals Trust becoming the first to receive this life-saving vaccine.
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
17 December 2020
Today, researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
8 December 2020
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
23 November 2020
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
19 November 2020
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build immunity.
12 November 2020
The University of Oxford has secured a critical professorship in vaccinology for the future following a gift of £3.33 million from the Saïd family. The gift will enable Professor Sarah Gilbert, the inaugural post holder, to continue her ground-breaking research in the field, while also helping to ensure that Oxford remains at the forefront of vaccine development for generations to come.
23 October 2020
Bvlgari and the University of Oxford’s Jenner Institute announce the next stage of their pledge to build a pandemic-free future by awarding the inaugural Bvlgari Scholarships.
22 September 2020
On Friday 18 September, Prime Minister Boris Johnson visited the Old Road Campus Research Building to meet senior researchers from the Medical Sciences Division. The Prime Minister heard about the developments, success and challenges at Oxford in relation to the University’s ongoing COVID-19 research.
2 September 2020
A new arm of the ongoing global clinical trials of the ChAdOx1 nCoV-19 vaccine led by AstraZeneca has launched in the US to assess safety, efficacy and immunogenicity of the vaccine for the prevention of COVID-19.
20 July 2020
The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a Phase I/2 randomized control trial
20 July 2020
The Phase 1 data shows that the vaccine raised no safety concerns, did not lead to any unexpected symptoms in those who received it, and was very similar to other vaccines of this type.
10 July 2020
A generous gift of £3.5 million from Lakshmi Mittal and his family has secured the future of a critical professorship in vaccinology at the University. The post, which is currently held by Professor Adrian Hill, will be known as the Lakshmi Mittal and Family Professorship of Vaccinology in recognition of this support.
27 June 2020
Volunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin America’s first phase 3 COVID-19 clinical trial. The trial officially began on Saturday 20th June and will enrol 5,000 volunteers across the country. Vaccinations will take place in Sao Paulo, Rio de Janeiro and a site in the Northeast of Brazil. The Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials on 2nd June, which are being conducted in partnership with AstraZeneca.
25 June 2020
The Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway. During his visit, The Duke was briefed about the Group’s work by Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford, who is leading the clinical trial team.
17 June 2020
Prof Sarah Gilbert from the Jenner Institute is speaking at a video linked Global Covid-19 vaccine congress on Monday 21st June 2020 organised by the International Society for Vaccines. The congress is free to scientists with an interest in COVID‐19 vaccines (pre‐registration required).
5 June 2020
The University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).
4 June 2020
On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
3 June 2020
On April 30, the University of Oxford and AstraZeneca announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. A Phase I/II clinical trial of the Oxford vaccine began in April in the UK to assess safety and immune response in over 1,000 healthy volunteers aged 18 to 55 years across several trial centres in southern England. As the vaccine trials move to Phase III, a larger population is being enrolled consisting of 10,000 participants in the UK with AstraZeneca enrolling 30,000 particpants in the US. On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
2 June 2020
On 13 May Professor Sarah Gilbert gave a short talk and participated in an informal discussion with ambassadors of the United Nations member states, hosted by the UK mission. Here is a summary of her talk.